News & Press Release

  • Press Releases
  • News
ZymagenX Announces Acceptance of Celiac Disease Quality of Life Study for Publication in GastroHep
July 8, 2026
ZymagenX Selected for Featured Scientific Presentations at DDW 2026
February 26, 2026
ZymagenX Breakthrough Research on Celiac Disease to be Featured at Prestigious Tampere Symposium
August 21, 2025
ZymagenX Delivers Invited Talk at International Symposium
May 8, 2025
ZymagenX Launches with Goal to Develop Latiglutenase
May 6, 2025
ImmunogenX Delivers Invited Talk at International Symposium
May 6, 2023
ImmunogenX and Mayo Clinic Celiac Disease Study Published in Gastroenterology
August 12, 2022
ImmunogenX Highlighted at Pre-Eminent Celiac Disease Conference
May 17, 2022
ImmunogenX to Make Highlighted Presentations at DDW 2022
February 23, 2022
ImmunogenX to Make Highlighted Presentations at DDW 2017
February 23, 2022
ImmunogenX and Mayo Clinic Successfully Complete the CeliacShield Trial
March 18, 2021
ImmunogenX Receives a Tibbetts Award
February 18, 2021
ImmunogenX Publishes in Celiac Disease Journal
August 11, 2020
ImmunogenX and Mayo Clinic CeliacShield Trial for Latiglutenase Passes Safety and Efficacy Midterm Assessment
July 2, 2020
Enrollment Begins for Latiglutenase (IMGX003) Phase 2b Trial for Treatment of Celiac Disease
February 13, 2020
Contact Us
ZymagenX
1600 Dove Street, Suite 330, Newport Beach, CA, 92660
Copyright © 2025 ZymagenX, Inc.